Key points from article :
Morphoceuticals has closed an $8m Seed-2 funding round led by Prime Movers Lab and Juvenescence.
Pioneering the use of AI-guided electroceuticals to regenerate limbs, repair tissues, and regenerate organs.
Successfully demonstrated limb regeneration in an African clawed frog.
A drug cocktail applied in a wearable bioreactor on the frog's hind leg for 24 hours triggered an 18-month period of leg regrowth and restored its functionality.
Morphoceuticals’ goal is to identify our body’s triggers for complex anatomical outcomes.
“By controlling bioelectric signaling, we are seeking to eventually generate functional tissues, limbs, and organs in humans, which could greatly improve the quality of life for patients,” - Michael Levin, co-founder of Morphoceuticals.
“Funding will enable...the development of tools that will map the bioelectric atlas of living tissues, which will be a discovery and development engine for our future therapeutics,” - Michael Hufford, CEO of Morphoceuticals.
Findings were published in Science Advances.
